On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a primary focus on bladder cancer treatment regimen.
The clinical-stage biotechnology company is focused on developing therapies for oncology and central nervous system conditions, with NDV-01 and sepranolone as lead candidates.
Phase 2 Data Highlight NDV-01’s Potential In NMIBC
In March, Relmada released promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer (NMIBC).
The 12-month interim data from the ongoing Phase 2 trial showed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population.
